The gap between a cannabis licence and EU GMP compliance
European cannabis regulation is converging on the pharmaceutical standard. That is not a future aspiration — it is the current legal reality in Germany, Portugal, the Netherlands and increasingly across every market where medical cannabis is licensed. The EU GMP requirements, the Annex 1 obligations, the pharmacopoeial product standards: they apply now, and regulators are inspecting to them now.
The gap between that regulatory expectation and the operational reality of most cannabis facilities is substantial. Many facilities hold licences that were granted on the basis of intent and infrastructure. Fewer can demonstrate the qualification programmes, validated processes, documented quality systems and data integrity standards that pharmaceutical manufacturing requires and that regulatory inspectors will look for.
ECI was founded to close that gap — not through aspirational guidance but through practical, practitioner-authored training that produces real compliance outputs, and through intelligence that gives operators the regulatory clarity they need to invest in the right areas.
ECI is an intellectual property organisation. The frameworks, assessments, courses, certifications, reports and standards we develop are assets that can serve thousands of practitioners and operators. That model — building knowledge infrastructure once and deploying it at scale — is how ECI can have the impact the sector needs.